Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in metastatic castration-resistant prostate cancer after abiraterone and docetaxel
ChiCTR2000037377Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Progression-free survival and Quality of life. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2000037377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037377.